Boston Trust Walden Corp Acquires 6,670 Shares of Novo Nordisk A/S $NVO

Key Points

• Boston Trust Walden Corp increased its stake in Novo Nordisk A/S by 124.3%, now holding a total of 12,036 shares worth approximately $831,000 as of its latest SEC filing.
• NVO's recent earnings report indicated a quarterly EPS of $0.97, exceeding analysts' expectations of $0.93, while revenue hit $11.69 billion.
• The company declared a semi-annual dividend of $0.4119 with a yield of 240.0%, while maintaining a dividend payout ratio (DPR) of 22.53%.

Boston Trust Walden Corp boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 124.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,036 shares of the company's stock after purchasing an additional 6,670 shares during the period. Boston Trust Walden Corp's holdings in Novo Nordisk A/S were worth $831,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $27,000. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $30,000. Disciplina Capital Management LLC increased its position in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after purchasing an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $35,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $56.72 on Thursday. The stock has a 50-day moving average price of $56.03 and a 200 day moving average price of $62.94. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $253.23 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 2.60 and a beta of 0.68. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $119.07.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Hsbc Global Res upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 1st. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Morgan Stanley cut Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and decreased their target price for the stock from $59.00 to $47.00 in a report on Monday, September 29th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $76.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.